NVHR: New data finding less than 1-in-5 hepatitis C patients receiving antiviral therapy
WASHINGTON New peer-reviewed data finding that fewer than one-fifth of the nearly 4 million Americans infected with chronic hepatitis C virus have received antiviral therapy in recent years should be a wake-up call that Congress needs to move urgently on bipartisan legislation to support new state-based detection, research, and surveillance efforts, the National Viral Hepatitis Roundtable said Tuesday.
The research trends identified in the new study were conducted by researchers at the University of Michigan and published in the December issue of Hepatology, a journal of the American Association for the Study of Liver Diseases. Among the key findings:
- Only about 663,000 of the estimated 3.9 million Americans infected with chronic hepatitis C virus received antiviral therapy between 2002 and 2007
- Treatment rates appear to be declining in part because only one-half of all HCV patients know they are infected
- Barriers to HCV screening including the absence of health insurance coverage, limited access to standard medical care, and lower priority of HCV testing by primary care physicians; and
- Increased public health efforts are needed to improve access to antiviral therapy and the researchers recommend further research of health services delivery and quality of care for HCV patients.
NVHR, a coalition dedicated to reducing the incidence of infection, morbidity, and mortality from viral hepatitis in the United States, warned that without congressional action, millions of Americans infected with chronic hepatitis C virus are at serious risk of developing cirrhosis, liver cancer, and liver failure, which will add billions of dollars in unnecessary costs to our healthcare system every year, NVHR said. According to research firm Milliman, the cost of chronic hepatitis C virus infection alone could reach $85 billion annually by 2024.
Last month, bipartisan legislation, The Viral Hepatitis and Liver Cancer Control Act, was introduced in the House of Representatives by Reps. Mike Honda, D-Calif., and Charles Dent, R-Pa., and co-sponsored by 10 House members. H.R. 3974 would support a comprehensive prevention, research, and medical management referral program for chronic hepatitis B and chronic hepatitis C virus infection. The bill would provide a relatively modest $90 million in funding in 2011 (with additional funding thereafter) that will increase the ability of the Centers for Disease Control and Prevention to support state health departments in their prevention, immunization and surveillance efforts.
“These shocking data should serve as a wake-up call that current public-health detection, treatment, and surveillance efforts for chronic hepatitis C viral infection are wholly inadequate,” said NVHR chair Lorren Sandt. “In terms of detection and treatment, the proverbial low-hanging fruit has been picked. In order to help our system reach under-served populations, Congress needs to act now on the bipartisan Honda-Dent legislation. Without action from Washington to support state-based efforts, millions of Americans will suffer from severe hepatitis-related complications and cost our health system tens of billions of dollars annually in avoidable medical costs.”
FDA approves Pharmaforce’s dorzolamide hydrochloride eye drops
ROCKVILLE, Md. The Food and Drug Administration has approved a drug for treating high pressure in the eye, a condition that eventually can lead to blindness.
FDA records show that the agency approved Pharmaforce’s dorzolamide hydrochloride eye drops.
The drug is used to treat high pressure in the eye resulting from open-angle glaucoma and ocular hypertension and is a generic version of Merck & Co.’s Trusopt.
FDA approves Amneal’s GERD generic
ROCKVILLE, Md. The Food and Drug Administration has approved a generic version of a drug for treating gastroesophageal reflux disease in adolescents and adults.
According to FDA records, the agency approved Amneal Pharmaceuticals’ nizatidine oral solution in the 15-mg-per-15-mL strength.
The drug is used to treat symptoms of GERD in patients ages 12 years and older and is a generic version of Axid, made by Braintree Laboratories.